Skip to main content
Quest Diagnostics

Development and Evaluation of Total RNA Sequencing Quality Controls for Blood-Based Biomarker Discovery

AMP 2023

Association for Molecular Pathology

Salt Lake City, UT, Nov 14-18 2023

Poster presentation: Development and Evaluation of Total RNA Sequencing Quality Controls for Blood-Based Biomarker Discovery

Authors: Sesler CL, Shaginurova GI, Wylezinski LS, Gray JD, Grigorenko EV, Cockerill FR, III, Larsen JA, Racke MK, Spurlock CF, III

Specialty: Oncology

Related content

Publication
Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology
Conference Presentation
Analytical validation and performance characteristics of a 523-gene next-generation sequencing panel for comprehensive genomic profiling in solid tumors
On-Demand Webinar
Hemepath Master Class Myeloid Neoplasms MPN MDS AML

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.